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Summary
Background: To analyse trends in incidence, survival and risk
of second neoplasms following vaginal and vulvar cancers
using data collected by the Swiss Cancer Registry of Vaud over
the 21-year period 1974-1994.
Materials and methods: Subjects were 257 vulvo-vaginal
cancers. Of these, 69 were vaginal, 153 vulvar cancers, and 35
non-specified lower genital tract neoplasms; 94 in situ neo-
plasms were also registered (85 for the vulva).
Results: Invasive vaginal cancer incidence decreased from
0.8 in 1974-1984 to 0.4/100,000 women in 1985-1994, while
invasive vulvar cancer incidence remained approximately stable
around 1.2/100,000 (world standard); incidence of in situ
vulvar cancer increased from 0.8 to 1.3/100,000, the rise being
larger in younger women. Significant excesses for second
primary neoplasms were observed for oro-pharyngeal and
lung cancer, and for non-melanomatous skin neoplasms, as
well as for invasive vulvar cancers following in situ cancers.
Conclusions: This population-based dataset confirms that
the incidence of in situ vulvar (but not invasive vulvar or
vaginal cancer) has been increasing over the last 20 years. The
excess second primary neoplasms supports the hypotheses that
human papillomavirus and cigarette smoking are related to
vulvo-vaginal neoplasms.
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Introduction
Cancers of the vagina and vulva are rare neoplasms,
accounting for less than 1% of all cancers in women, and
9% of female genital tract neoplasms [1].
Most information on descriptive epidemiology of
these neoplasms comes from the Surveillance Epidemi-
ology and End Results (SEER) Program of the US
National Cancer Institute [2, 3]. The SEER data over
the period 1973-1987 showed no appreciable change
over time for vaginal and invasive vulvar cancer, with
age-standardized incidence rates (on the US population)
around 1.0 and 1.5/100,000, respectively. In contrast, the
incidence rate of in situ vulvar cancer nearly doubled
between 1973 and 1987, the rise being particularly
marked below age 55 [2]. Five-year relative survival was
over 90% for vulvar cancers, and less than 50% for
vaginal neoplasms [3]. Selected clinical series [4] gave
five-year survival of about 60% for vulvar and 50% for
vaginal carcinomas. An excess of secondary primary
cancers after vulvar and vaginal cancers was found for
smoking or human-papillomavirus (HPV) related neo-
plasms [5]. A significant excess of invasive vulvar cancer
following vulvar intra-epithelial neoplasia was also re-
ported [6].
Most other data come from hospital-based series.
They confirmed an increase of intra-epithelial vulvar
neoplasia, mostly at younger age [7-10]. These trends
have been associated to changed sexual habits in most
recent cohorts of women, infection with HPV, and
smoking [11-13].
To provide further, population-based information on
incidence, survival and second neoplasms following
vaginal and vulvar cancers, we analysed data from the
Cancer Registry of Vaud over the 21-year period 1974—
1994.
Materials and methods
Vulvo-vaginal cancer incidence data for the period 1974-1994 were
abstracted from the Vaud Cancer Registry file, which includes data
concerning incident cases of malignant neoplasms in the Canton
(whose population according to the Census 1990 was about 580,000
inhabitants) [1].
Information collected by the register includes general demographic
characteristics of the patient (age, sex, municipality of residence), site
and histological type of the tumour according to the International
Classification of Diseases for Oncology [14], and time of diagnostic
confirmation.
The present series comprises 257 invasive vulvo-vaginal cancer
primaries (ICD-0 T: 184.0, vagina, n = 69; 184.1-184.4, vulva, n =
153; 184.8-184.9, non specified lower genital tract neoplasms, n = 35)
registered during the 21 year period from 1974 to 1994. Ninety-five
histologically verified in situ vulvo-vaginal neoplasms were also regis-
tered (85 for the vulva; 56% being labeled as Bowen's disease). Histo-
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Table 1. Trends in age-standardized incidence rates* of invasive and in
situ neoplasms of the vagina, vulva and of unspecified neoplams of the
lower female genital tract in Vaud, Switzerland, 1974-1994.
Site
Vagina
Vulva
Unspecified
Invasive
In situ
Invasive
In silu
Invasive
Calendar period
1974-1984
Number
45
3
71
33
23
Rate"
0.8
0.08
1.1
0.8
0.3
1985-1994
Number
24
6
82
52
12
Rate"
0.4
0.1
1.3
1.3
0.1
Table 2. Trends in age-standardized incidence rates* of invasive and
in situ neoplasms of the vagina, vulva and in separate age groups in
Vaud, Switzerland, 1974-1994.
Site Calendar period
1974-1984 1985-1994
Rate at age Rate at age
Vagina
Vulva
Invasive
Invasive
In situ
20-^4
0.2
0.3
1.0
45-64
2.2
1.2
1.9
4
10
1
65
.5
.7
.8
20-44
0.2
0.6
2.2
45-64
1.2
2.8
1.9
1
8
3
s6 i
.9
.0
.1
* Rate per 100,000 women, age-standardized on the world population. * Rate per 100,000 women, age-standardized on the world population.
logical confirmation was performed in over 92% of the invasive neo-
plasms, and only 2.5% were discovered at death.
Age-standardized incidence rates (by the direct method, world
standard population) were computed for the population of all ages
and for three separate age groups (20-44,45-64 and 65 or more years).
Mean annual percent changes were derived from standard log-linear
regression models.
Information on survival was derived from mortality statistics and,
for 'apparently' non-deceased cases, through an active follow-up based
on verification of vital status from registries of current residence [14].
Patients who migrated outside the Canton, and were therefore not
traceable (2.3%), were censored at the date of emigration. The vital
status of each registered case has thus been verified up to June 30th,
1997. One-, three-, five- and 10-year relative survival estimates were
computed after allowance for the general lifetables of the Canton [15]
Invasive and in situ cases were followed-up to 31 December 1996
for the occurrence of second primary neoplasms, for a total of 1,502
person-years at risk (918 for invasive neoplasms). Calculation of
expected numbers of cases were based on site-, age- and calendar
period-specific incidence rates, multiplied by the corresponding num-
ber of person-years at risk. The significance of the observed: expected
ratios (standardized incidence ratio (SIR)) and their corresponding
95% confidence intervals (95% CI) was based on the Poisson distribu-
tion [16].
Results
Over the period 1974-1994, 257 vulvo-vaginal invasive
cancers were registered. Of these, 69 were vaginal neo-
plasms (51, 74% squamous cell), 153 vulvar cancers (114,
75% squamous cell) and 35 were non specified lower
genital tract neoplasms. A total of 94 in situ neoplasms
were also registered; of them, 85 were from the vulva.
Table 1 gives the age-standardized (world standard)
incidence rates in two separate calendar periods (1974—
1984; 1985-1994). Incidence of invasive vaginal cancer
decreased from 0.8 to 0.4/100,000 women, while inva-
sive vulvar cancer remained approximately stable (1.1 in
1974-1984; 1.3 in 1985-1994). Other invasive lower
female genital tract neoplasms declined from 0.3 to
0.1/100,000. In contrast, some rise was observed for in
situ vaginal cancers (from 0.08 to 0.1/100,000 women)
and for in situ vulvar cancers (from 0.8 to 1.3/100,000).
The estimated percent annual changes were -3.7% and
+2.6% for invasive neoplasms of vagina and vulva,
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Figure 1. Survival curves of invasive cancers of vagina, vulva and
unspecified female lower genital tract neoplasms in Vaud, Switzerland,
1974-1994.
respectively, and +1.2% and +5.1% (P - 0.05) for vaginal
and vulvar in situ neoplasms.
Table 2 gives corresponding figures in three separate
age groups (20-44,45-64, ^65 years). While the decline
for invasive vaginal cancer was observed both at age 45
to 64 and in elderly women, the rise for in situ vulvar
cancer was larger below age 45, and under age 65 there
was also some increase in invasive vulvar cancers.
Survival rates are plotted in Figure 1 (for invasive
neoplasms) and given in Table 3 in terms of relative
survival. These were 41% at 10 years for invasive vaginal
cancer, 48% for invasive vulvar cancer, and 94% for in
situ vulvar neoplasms.
Observed and expected numbers of second neoplasms
following vaginal and vulvar neoplasms are given in
Table 4. Excess rates were observed for oro-pharyngeal
cancers following invasive vulvar and vaginal cancers
(two observed, 0.2 expected; SIR = 10.3), and for tobacco-
related neoplasms (oro-pharyngeal and lung) following
combined invasive and in situ vulvar and vaginal cancers
(seven observed, 0.8 expected; SIR = 9.0; 95% CI: 3.6-
18.5). Furthermore, there was a significant excess of
invasive vulvar cancer following in situ cancer (four
observed, 0.03 expected). Rates were also significantly
above unity for non-melanomatous skin cancer follow-
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Table 3. One-, three-, five- and ten-year relative survival for in situ and
malignant neoplasms of vagina, vulva and unspecified female lower
tract neoplams in Vaud, Switzerland, 1974-1994.
Site Relative survival at
One
year
Three
years
Five
years
Ten
years
Vagina Invasive 0.72 0.45 0.41 0.41
Vulva In situ 0.97 0.95 0.95 0.94
Invasive 0.84 0.68 0.60 0.48
Unspecified Invasive 0.27 0.24 0.05 NC
Abbreviation: NC - not computable.
Table 4. Observed and expected cases, and standardized incidence
ratios (SIR) of subsequent cancer sites after an initial diagnosis of in
situ or invasive neoplasm of vagina and vulva, and corresponding 95%
CI of the SIR. Vaud, Switzerland, 1974-1994.
Site of second primary
First vagina, invasive
Oropharynx
Skin, non-melanoma
Total, all sites'"
Total, excl. skinb
First vulva, invasive
Oropharynx
Colorectum
Lung
Skin, non-melanoma
Total, all sites*
Total, excl. skin"
Total invasive0
Oropharynx
Colorectum
Lung
Skin, non-melanoma
Total, all sites'1
Total, excl. skind
First vulva, in situ
Lung
Skin, non-melanoma
Vulva
Total, all sites'
Total, excl. skine
Number of cases
Observed
1
3
5
2
1
4
2
7
17
10
2
5
2
10
22
12
3
6
4
16
10
Expected
0.1
0.9
3 5
2.3
0.1
1.2
0.3
2.7
9.8
7.2
0.2
1.7
0.5
3.7
13.7
9.4
0.2
1.3
0.03
5.1
3.2
SIR
20.3
3.4
1.4
0.9
72
3.3
5.8
2.6
1.7
1.4
10.3
3.0
4.1
2.7
1.6
1.3
14.7
4.5
139.2
3.1
3.1
95% CI
0.3-112.8
0.7-10.0
0.5-3.4
0.1-3.2
0.1-39.9
0.9-8.5
0.7-21.1
1.0-5.4
1.0-2.8
0.7-2.5
1 2-37.1
1.0-8.0
0.5-15.0
1.3-5.0
1.0-2.4
0.7-2.2
3.0-43.0
1.7-9.8
37.5-336.4
1.8-5.1
1.5-5.7
* Includes one breast (1.9 expected), one ovarian neoplasm (0.3
expected), and one multiple myeloma (0.1 expected).
b
 Includes one colorectal cancer (0.4 expected).
c
 Includes vulvar, vaginal and unspecified neoplasms.
d
 Includes one breast (2.7 expected), one ovarian neoplasm (0.4
expected), and one multiple myeloma (0.1 expected).
' Includes one colorectal (0.5 expectd), one liver (0.02 expected), and
one breast neoplasm (1.2 expected).
excess was observed for colorectal cancer (five observed,
1.7 expected; SIR = 3.0) following invasive vulvo-vaginal
cancer.
Discussion
The incidence rates of invasive and in situ vulvar and
vaginal neoplasms in this European population were of
similar magnitude as those reported from the SEER
Program in the United States [2, 3, 18, 19] and also
trends in incidence were in the same direction, with
some decline in vaginal cancer, but a rise in vulvar
cancer, mostly at younger age and for in situ neoplasms.
Likewise, the five- and 10-year survival rates (over 90%
for in situ neoplasms, less than 50% for invasive vaginal
and vulvar neoplasms) are well comparable with avail-
able data from the SEER Program [2, 3, 17, 18] and
clinical series [4, 7-10].
The data were derived from a population-based can-
cer registry system established for over 20 years, and
adopting the same criteria of registration for invasive
and in situ vulvo-vaginal neoplasms [1]. A limitation of
the study, however, is given by the small number of
cases, particularly for in situ vaginal neoplasms.
The main interest and importance of this dataset is
therefore in confirming, on the basis of a population-
based series from Europe, a number of clinical observa-
tions [7-10] suggesting a rise in (in situ) vulvar cancers.
This finding has been usually related, as for cervical
cancer [19], to the changed sexual habits of younger
generations of women, and possibly to infection with
HPV [12, 13]. This hypothesis is supported by the excess
oral cancer following vulvo-vaginal cancers, since a role
of HPV on oral carcinogenesis has also been postulated
[20]. HPV has also been related to non-melanomatous
skin cancer [21, 22], although the issue remains open to
discussion. Likewise, the excess of lung, oral and other
tobacco-related neoplasms following vulvo-vaginal neo-
plasms supports a role for cigarette smoking, as reported
in case-control investigations [23-25].
The decline in invasive vaginal cancer, mostly in
middle and elderly age, is more difficult to explain, but
may be related to the increased frequency of Pap-smear,
as reflected by the fall in invasive cervical cancer ob-
served in the same population [26].
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ing invasive vulvar and vaginal cancers (10 observed, 3.7
expected; SIR = 2.7) as well as in situ cancers (six
observed, 1.5 expected; SIR = 4.1). A non significant
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